Regulus Therapeutics reported $49.24M in Equity Capital and Reserves for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Equity Capital And Reserves Change
Alnylam Pharmaceuticals ALNY:US $ 401.17M 187.04M
AstraZeneca AZN:LN 36340M 2928M
Astrazeneca AZN:US $ 36340M 2928M
Biogen BIIB:US $ 11242.3M 346.1M
Celldex Therapeutics CLDX:US $ 398.1M 21.38M
Gilead Sciences GILD:US $ 19927M 1142M
GlaxoSmithKline GSK:LN 16181M 1126M
Intercept Pharmaceuticals ICPT:US $ -371.76M 187.8M
Intrexon XON:US $ 73.84M 33.51M
Lexicon Pharmaceuticals LXRX:US $ 92.7M 20.9M
Ligand Pharmaceuticals LGND:US $ 793.19M 27.97M
Merk MRK:US $ 40883M 2699M
Omeros OMER:US $ -4925000 28.7M
Regulus Therapeutics RGLS:US $ 49.24M 5.72M
Sangamo Biosciences SGMO:US $ 334.52M 40.82M
Spectrum Pharmaceuticals SPPI:US $ 55.26M 7.7M
Takeda 4502:JP Y 5683019M 351690M
Vital Therapies VTL:US $ 137.96M 10.85M
YTE INCY:US $ 3863.07M 93.07M